Study S000586

A Multicenter, Randomized, Open-label and Parallel-controlled Phase III Study to Compare the Efficacy and Safety of Semaglutide Injection With Ozempic® in the Treatment of Type 2 Diabetes Subjects With Poor Glycemic Control on Metformin

ClinicalTrials.gov record

Registration

Registration: NCT06339086
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: UNKNOWN
Enrollment: 478
Start: 2024-04
Primary completion: 2025-08-30
Lead sponsor: Chengdu Brilliant Pharmaceutical Co., Ltd.
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:Semaglutide Injection; DRUG:Semaglutide Injection(Ozempic®); DRUG:Metformin
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change in HbA1c [Week 32]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.